Evidence Quality and Health Technology Assessment Outcomes in Reappraisals of Drugs for Rare Diseases in Germany
Authors:
Open Access
- 31 July 2024
- journal article
- research article
- Published by Elsevier in Value in Health
- Vol. 27 (12) , 1662-1670
Abstract
No abstract availableKeywords
Funding Information
- UK Research and Innovation Economic and Social Research Council
This publication has 19 references indexed in Scilit:
- Consideration of quality of life in the health technology assessments of rare disease treatmentsThe European Journal of Health Economics, 2021
- Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and TisagenlecleucelPharmacoEconomics, 2021
- Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and EuropeClinical Pharmacology & Therapeutics, 2020
- Determinants of Orphan Drug Prices in GermanyPharmacoEconomics, 2020
- HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countriesHealth Policy, 2019
- Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved DrugsClinical Pharmacology & Therapeutics, 2018
- Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare DiseasesValue in Health, 2018
- Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA AgenciesValue in Health, 2017
- Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislationThe European Journal of Health Economics, 2013
- Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for CancerJAMA, 2011